stockrow10x Genomics
TXG Healthcare Medical Devices
10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
- Revenue
- +1.12%
- EPS
- +31.8%
- Free cash flow
- −4.61%
Quarter to September 2026, against a year earlier
Follow TXG
Alert me
10x Genomics (TXG) Current ratio
10x Genomics's current ratio at the end of the quarter to 30 September 2026 was 5.1×, up 0.7× from fiscal 2025 (4.5×). Over the past ten years it has ranged from 3.1× (fiscal 2017) to 7.6× (fiscal 2019); the current reading is higher than 33% of that period. That is above the Medical Devices industry median of 2.7× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 4.5× | (10.22%) |
| FY2024 | 5.0× | 5.99% |
| FY2023 | 4.7× | (3.34%) |
| FY2022 | 4.8× | (28.42%) |
| FY2021 | 6.8× | 3.34% |
| FY2020 | 6.6× | (14.04%) |
| FY2019 | 7.6× | 132.32% |
| FY2018 | 3.3× | 6.21% |
| FY2017 | 3.1× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 5.1× | (10.07%) |
| Jun 2026 | 5.7× | (3.44%) |
| Mar 2026 | 5.9× | 32.18% |
| Dec 2025 | 4.5× | (0.41%) |
| 25 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| PEN Penumbra, Inc. compare | 5.9× |
| TXG 10x Genomics | 5.7× |
| GMED Globus Medical, Inc. compare | 4.3× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 3.2× |
| BIO Bio-Rad Laboratories, Inc. compare | 3.2× |
| HAE Haemonetics Corporation compare | 2.8× |
| PODD Insulet Corporation compare | 2.5× |
| SNN Smith & Nephew SNATS, Inc. compare | 2.1× |
| BRKR Bruker Corporation compare | 1.8× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on TXG
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement